Quick Answer
Kiniksa Pharmaceuticals International, plc reported Operating Income Loss of $77.22 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +269.3% in Operating Income Loss from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$11.39 million | Q3 2017: -$16.25 million | Q1 2018: -$16.34 million | Q2 2018: -$21.53 million | Q3 2018: -$26.16 million | Q1 2019: -$67.65 million | Q2 2019: -$39.29 million | Q3 2019: -$30.45 million | Q1 2020: -$29.39 million | Q2 2020: -$31.86 million | Q3 2020: -$43.22 million | Q1 2021: -$49.28 million | Q2 2021: -$40.56 million | Q3 2021: -$30.67 million | Q1 2022: -$23.32 million | Q2 2022: -$19.37 million | Q3 2022: $46.41 million | Q1 2023: -$11.20 million | Q2 2023: -$3.15 million | Q3 2023: -$10.93 million | Q1 2024: -$16.54 million | Q2 2024: -$117.0 thousand | Q3 2024: -$9.66 million | Q1 2025: $13.27 million | Q2 2025: $20.16 million | Q3 2025: $24.02 million.
- Over the full 9 years of available data (2017 to 2025), Kiniksa Pharmaceuticals International, plc's Operating Income Loss has grown by 218.1%.
- Historical annual values: Fiscal year 2025: $77.22 million | Fiscal year 2024: -$45.62 million | Fiscal year 2023: -$25.20 million | Fiscal year 2022: $9.77 million | Fiscal year 2021: -$156.64 million | Fiscal year 2020: -$157.36 million | Fiscal year 2019: -$169.96 million | Fiscal year 2018: -$108.16 million | Fiscal year 2017: -$65.40 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: